Your session is about to expire
← Back to Search
Behavioral Intervention
Brief Behavioral Activation Treatment for Postpartum Depression (SUMMIT Trial)
N/A
Waitlist Available
Led By Daisy R Singla, PhD
Research Sponsored by Mount Sinai Hospital, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
≥18 years
Be older than 18 years old
Must not have
Non-English, non-Spanish speakers
Active suicidal intent (ideation and plan), active symptoms of psychosis or mania
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 to 24 months post child birth (extended due to covid-19)
Awards & highlights
No Placebo-Only Group
Summary
This trial is examining whether a brief behavioral activation treatment delivered via telemedicine is as effective as the same treatment delivered in person, and whether the treatment delivered by non-mental health nurses is as effective as when delivered by specialist providers.
Who is the study for?
The SUMMIT trial is for pregnant women up to 36 weeks or those who are 4-30 weeks postpartum, experiencing depression with an EPDS score of at least 10. Participants must be over 18 and speak English or Spanish. It excludes those with severe fetal issues, recent infant death, active suicidal thoughts, psychosis, recent psychotropic medication changes, ongoing psychotherapy, substance abuse issues, or non-English/Spanish speakers.
What is being tested?
SUMMIT is testing the effectiveness of a brief Behavioral Activation Treatment for perinatal depression and anxiety delivered via telemedicine versus in-person. It also compares treatment by trained nurses to specialist providers like psychiatrists. The study aims to understand how well these methods work across different locations and patient groups.
What are the potential side effects?
Behavioral Activation Treatment generally has minimal side effects as it's a psychological therapy rather than a drug-based intervention. However, discussing emotional topics can sometimes cause temporary discomfort or distress.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not speak English or Spanish.
Select...
I do not have active suicidal thoughts or untreated psychosis.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 to 24 months post child birth (extended due to covid-19)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 to 24 months post child birth (extended due to covid-19)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Anxiety symptoms: Generalized Anxiety Disorder Scale (GAD-7) mean score
Child Mental Health Development
Depressive symptoms: Edinburgh Postnatal Depression Scale (EPDS) mean score
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: TelemedicineExperimental Treatment1 Intervention
A brief, manualized behavioral activation treatment delivered over Zoom™ in Toronto, via Webex™ in Chapel Hill, and via Zoom™ in NorthShore
Group II: Non-specialistExperimental Treatment1 Intervention
Trained non-mental health providers (e.g., nurses or midwives) with general healthcare professional skills (as assessed during recruitment) with no previous experience delivering psychological treatments implementing a brief, manualized behavioral activation treatment
Group III: SpecialistActive Control1 Intervention
Psychiatrists, psychologists and social workers with experience in treating perinatal mental illness and a minimum of 5 years of experience delivering psychological treatments delivering a brief, manualized behavioral activation treatment
Group IV: In-PersonActive Control1 Intervention
A brief, manualized behavioral activation treatment delivered in-person held at participating clinical care sites within UToronto, UNC and NorthShore
Find a Location
Who is running the clinical trial?
University of North Carolina, Chapel HillOTHER
1,548 Previous Clinical Trials
4,268,024 Total Patients Enrolled
6 Trials studying Postpartum Depression
278 Patients Enrolled for Postpartum Depression
Sunnybrook Health Sciences CentreOTHER
672 Previous Clinical Trials
1,564,505 Total Patients Enrolled
1 Trials studying Postpartum Depression
156 Patients Enrolled for Postpartum Depression
Harvard Medical School (HMS and HSDM)OTHER
201 Previous Clinical Trials
1,315,099 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not speak English or Spanish.I speak English or Spanish.You are currently addicted to drugs or alcohol.My psychotropic medication dose hasn't changed in the last two weeks.The pregnancy resulted in a severe birth defect or stillbirth, or the baby died soon after birth at the time you are considering joining the study.I do not have active suicidal thoughts or untreated psychosis.I am 18 years old or older.I am currently pregnant (up to 36 weeks) or recently had a baby (4-30 weeks ago).I am currently in psychotherapy, but it's less frequent than once every 8 weeks.
Research Study Groups:
This trial has the following groups:- Group 1: Specialist
- Group 2: Telemedicine
- Group 3: Non-specialist
- Group 4: In-Person
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger